Research and patient care programs at UCSF in immunology, immune disorders and infectious diseases are regarded as national models, with UCSF scientists recognized for some of the most influential advances in basic science research. Their work has revealed the underpinnings of immune action and infection – insights that are pointing the way to better treatments. This expertise also translates into outstanding educational programs. 

Stephanie Wangler, left, Lupus programs coordinator and Maria Dall 'Era, MD, director and associate professor, rheumatologist at the Lupus Clinic.

National rankings underscore UCSF’s high caliber. The 2010-2011 US News & World Report survey on the nation’s best hospitals names UCSF patient care programs in diabetes, endocrine disorders and rheumatology among the top 10, and the US News & World Report survey on best graduate schools ranks UCSF training in HIV/AIDS and in immunology and infectious diseases as the premier programs in the country: No. 1 and No. 2, respectively.

“UCSF has developed a superb research partnership in immunology and infectious diseases; the rate of progress is only accelerating,” says Jeffrey Bluestone, PhD, UCSF executive vice chancellor and provost and A.W. and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology. 

“UCSF has become a world leader in research to understand how the key molecular players interact to trigger disease – whether initiated by pathogens or by the body’s own immune system. Scientists focusing on both routes of disease interact intensively here, and their collaborations are speeding progress to new therapies,” says Bluestone.

Patients benefit directly from the collaboration of UCSF basic science and clinical research teams and from the opportunity to enroll in numerous clinical trials, which are testing new treatments for immunological and infectious diseases and available at UCSF as a leading academic medical center.

Among other achievements in these specialties, UCSF is recognized for pioneering strategies to more precisely target the causes of immune system disorders and transplant rejection, while reducing treatment side effects, and for contributing to new approaches to treat diabetes, rheumatoid arthritis, lupus, cancer, airway diseases and organ rejection.

Infectious diseases teams established UCSF at the forefront of research and clinical excellence in HIV- and AIDS-related diseases in the early 1980s, and today the UCSF treatment model, developed in collaboration with UCSF-affiliated San Francisco General Hospital, is used around the world.